Cargando…

PB2164: PROGNOSTIC IMPACT OF ONCOGENE DEK IN DIFFUSE LARGE B-CELL LYMPHOMA

Detalles Bibliográficos
Autores principales:	Alonso Alonso, R., Rodríguez, M., Privette Vinnedge, L. M., Serrano, J., Jiménez de las Pozas, Y., G Pedrero, S., Laínez, D., García Raso, A., Alonso Dominguez, J. M., López García, A., Córdoba, R., Piris, M. A., Llamas Sillero, P., Sánchez García, J., Serrano Lopez, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429094/ http://dx.doi.org/10.1097/01.HS9.0000851484.14600.15

Ejemplares similares

PB2165: BIOINFORMATIC TOOL FOR IMMUNOMODULATING THE ONCOGENIC TRANSCRIPTOME OF ABC-DLBCLS
por: Rodríguez, M., et al.
Publicado: (2022)

The DEK Oncogene Is a Target of Steroid Hormone Receptor Signaling in Breast Cancer
por: Privette Vinnedge, Lisa M., et al.
Publicado: (2012)

The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor positive breast cancers
por: Privette Vinnedge, Lisa M., et al.
Publicado: (2014)

Dissecting the Potential Interplay of DEK Functions in Inflammation and Cancer
por: Pease, Nicholas A., et al.
Publicado: (2015)

The human DEK oncogene stimulates beta catenin signaling, invasion and mammosphere formation in breast cancer
por: Privette Vinnedge, Lisa M., et al.
Publicado: (2011)

Novel molecular mechanisms in Alzheimer’s disease: The potential role of DEK in disease pathogenesis
por: Greene, Allie N., et al.
Publicado: (2022)

PB1820: THE EFFECT OF CONVENTIONAL CHEMOTHERAPY AFTER EXITING QUIESCENT STATE IN ACUTE MYELOID LEUKAEMIA
por: Láinez-González, Daniel, et al.
Publicado: (2023)

DEK Expression in Breast Cancer Cells Leads to the Alternative Activation of Tumor Associated Macrophages
por: Pease, Nicholas A., et al.
Publicado: (2020)

PB1827: TWO-LEVEL INHIBITION OF HEDGEHOG SIGNALLING PATHWAY TO EXIT QUIESCENT STATE IN ACUTE MYELOID LEUKAEMIA
por: Láinez-González, Daniel, et al.
Publicado: (2023)

Loss of DEK Expression Induces Alzheimer’s Disease Phenotypes in Differentiated SH-SY5Y Cells
por: Greene, Allie N., et al.
Publicado: (2020)

PB2164: EFFICACY AND SAFETY EVALUATION OF IXAZOMIB, POMALIDOMIDE, AND DEXAMETHASONE IN THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: LI, Wen, et al.
Publicado: (2023)

DEK is required for homologous recombination repair of DNA breaks
por: Smith, Eric A., et al.
Publicado: (2017)

A Multidisciplinary Journey towards Bone Tissue Engineering
por: Pedrero, Sara G., et al.
Publicado: (2021)

PB2325: VALIDATION OF THE TRAIL SCORE TO PREDICT TOXICITY IN PATIENTS WITH DLBCL RECEIVING R-CHOP-LIKE THERAPY
por: Caballero, Juan Carlos, et al.
Publicado: (2023)

The human DEK oncogene regulates DNA damage response signaling and repair
por: Kavanaugh, Gina M., et al.
Publicado: (2011)

Decreased plasma DEK Oncogene Levels Correlate with p16-Negative Disease and Advanced Tumor Stage in a Case–Control Study of Patients with Head and Neck Squamous Cell Carcinoma
por: Wise-Draper, Trisha, et al.
Publicado: (2017)

PROJECT ADMINISTRATION AGREEMENT KN2164
por: THE EUROPEAN ORGANIZATION FOR NUCLEAR RESEARCH, CERN, et al.
Publicado: (2012)

PB2129: COULD LYMPHOPENIA PREDICT OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA?
por: Merchan Muñoz, B., et al.
Publicado: (2022)

PB2193: IS HYPERHYDRATION NECESSARY FOR HIGH DOSE MELPHALAN CONDITIONING REGIMEN IN AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION?
por: Mora Argumánez, M., et al.
Publicado: (2022)

Role of the DEK oncogene in the development of squamous cell carcinoma
por: Ishida, Kazuhisa, et al.
Publicado: (2020)

PB2102: IMPACT OF AUTOLOGOUS STEM CELL TRASPLANTATION IN AL AMYLOIDOSIS. EXPERIENCE IN A SINGLE TERTIARY HOSPITAL
por: Alonso, Elena Alejo, et al.
Publicado: (2023)

2164. Resistome patterns associated with vancomycin non-susceptibility in clinical Clostridioides difficile isolates
por: Eubank, Taryn A, et al.
Publicado: (2023)

Cut-Off Values of Hematologic Parameters to Predict the Number of Alpha Genes Deleted in Subjects with Deletional Alpha Thalassemia
por: Velasco-Rodríguez, Diego, et al.
Publicado: (2017)

PB2491: LANGERHANS CELL HISTIOCYTOSIS (LCH) IN THE MAXILLOFACIAL AREA IN ADULT. COMPLETE REMISSION WITH CLADRIBINE. CASE REPORT AND REVIEW.
por: De Miguel Llorente, Dunia, et al.
Publicado: (2023)

PB2703: ISA-KD IN NOT TRANSPLANT CANDIDATES RRMM. EXPERIENCE IN REAL LIFE.
por: Llorente, Dunia De Miguel, et al.
Publicado: (2023)

PB2624: CLINICAL WHOLE EXOM SEQUENCING FOR CONGENITAL PLATELET DISORDERS: ONE SINGLE CENTER EXPERIENCE
por: Piñeiro, Victor Portela, et al.
Publicado: (2023)

Understanding the Hedgehog Signaling Pathway in Acute Myeloid Leukemia Stem Cells: A Necessary Step toward a Cure
por: Lainez-González, Daniel, et al.
Publicado: (2021)

Understanding the Notch Signaling Pathway in Acute Myeloid Leukemia Stem Cells: From Hematopoiesis to Neoplasia
por: Láinez-González, Daniel, et al.
Publicado: (2022)

PB2070: EFFICACY OF RITUXIMAB MAINTENANCE THERAPY IN ADVANCED-STAGE FOLLICULAR LYMPHOMA: A SINGLE-CENTER RETROSPECTIVE STUDY.
por: Amorós, C., et al.
Publicado: (2022)

Overexpression of the human DEK oncogene reprograms cellular metabolism and promotes glycolysis
por: Matrka, Marie C., et al.
Publicado: (2017)

PB2292: DEVELOPMENT OF CARDIOTOXICITY NEGATIVELY IMPACTS IN OVERALL SURVIVAL IN PATIENTS WITH LYMPHOMA TREATED WITH FIRST-LINE ANTHRACYCLINES
por: Garcia, Alberto Lopez, et al.
Publicado: (2023)

PB2266: TRIAL IN PROGRESS: PHASE 3 TRIAL OF ODRONEXTAMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA (OLYMPIA-5)
por: Vitolo, Umberto, et al.
Publicado: (2023)

PB2340: INFLUENCE OF INITIAL CLINICAL FEATURES IN THERAPEUTIC DECISIONS AND DIAGNOSTIC PROCESS OF ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA. A REAL WORLD EXPERIENCE
por: Bolea, L., et al.
Publicado: (2022)

PB2084: FIRST-LINE TREATMENT IN ADVANCED STAGE FOLICULAR LYMPHOMA: A SINGLE-CENTER EXPERIENCE WITH R-CHOP VS BENDAMUSTINE-RITUXIMAB.
por: Mompel, O., et al.
Publicado: (2022)

PB2105: REAL WORLD EXPERIENCE WITH POLATUZUMAB IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB FOR R/R DLBCL IN 3 ACADEMIC CENTERS IN MADRID, SPAIN.
por: Corrochano, M., et al.
Publicado: (2022)

PB2328: CHRONIC LYMPHATIC LEUKAEMIA (CLL) ASSOCIATED TO ACQUIRED FACTOR V INHIBITOR. A CASE REPORT.
por: Porro Camarero, A., et al.
Publicado: (2022)

PB2047: MOLECULAR DIAGNOSIS OF CONGENITAL ERYTHROCYTOSIS IN A SINGLE HOSPITAL CENTER.
por: Castilla Garcia, L., et al.
Publicado: (2022)

PB2628: EXPERIENCE AT THE GUADALAJARA UNIVERSITY HOSPITAL (SPAIN) IN FETAL AND NEONATAL ALLOINMUNE THROMBOCYTOPENIA (FNAIT) DURING EIGHT YEARS.
por: López, María Irene Nuevo, et al.
Publicado: (2023)

PB2384: EVALUATION OF NEW MACHINE LEARNING SYSTEMS FOR PROGNOSTICATION BASED ON GENE EXPRESSION SIGNATURES IN MANTLE CELL AND PERIPHERAL T CELL LYMPHOMAS
por: Mosquera-Orgueira, Adrian, et al.
Publicado: (2023)

The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer
por: Martinez-Useros, J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ncqdbff0b0oobb71p9uuuviom5